Department of Food Science and Technology, Pukyong National University, Busan, 48513, Republic of Korea; Marine Integrated Biomedical Technology Center, The National Key Research Institutes in Universities, Pukyong National University, Busan, 48513, Republic of Korea; Research Center for Marine Integrated Bionics Technology, Pukyong National University, Busan, 48513, Republic of Korea.
Marine Integrated Biomedical Technology Center, The National Key Research Institutes in Universities, Pukyong National University, Busan, 48513, Republic of Korea; Research Center for Marine Integrated Bionics Technology, Pukyong National University, Busan, 48513, Republic of Korea; Institute of Fisheries Science, Pukyong National University, Busan, 48513, Republic of Korea; International Graduate Program of Fisheries Science, Pukyong National University, Busan, 48513, Republic of Korea.
Int J Antimicrob Agents. 2024 Aug;64(2):107243. doi: 10.1016/j.ijantimicag.2024.107243. Epub 2024 Jun 20.
Polymicrobial biofilms are among the leading causes of antimicrobial treatment failure. In these biofilms, bacterial and fungal pathogens interact synergistically at the interspecies, intraspecies, and interkingdom levels. Consequently, combating polymicrobial biofilms is substantially more difficult compared to single-species biofilms due to their distinct properties and the resulting potential variation in antimicrobial drug efficiency. In recent years, there has been an increased focus on developing alternative strategies for controlling polymicrobial biofilms formed by bacterial and fungal pathogens. Current approaches for controlling polymicrobial biofilms include monotherapy (using either natural or synthetic compounds), combination treatments, and nanomaterials. Here, a comprehensive review of different types of polymicrobial interactions between pathogenic bacterial species or bacteria and fungi is provided along with a discussion of their relevance. The mechanisms of action of individual compounds, combination treatments, and nanomaterials against polymicrobial biofilms are thoroughly explored. This review provides various future perspectives that can advance the strategies used to control polymicrobial biofilms and their likely modes of action. Since the majority of research on combating polymicrobial biofilms has been conducted in vitro, it would be an essential step in performing in vivo tests to determine the clinical effectiveness of different treatments against polymicrobial biofilms.
多微生物生物膜是导致抗菌治疗失败的主要原因之一。在这些生物膜中，细菌和真菌病原体在种间、种内和种间水平上协同相互作用。因此，与单一物种生物膜相比，对抗多微生物生物膜要困难得多，因为它们具有独特的特性，导致抗菌药物效率可能存在差异。近年来，人们越来越关注开发控制细菌和真菌病原体形成的多微生物生物膜的替代策略。控制多微生物生物膜的当前方法包括单疗法（使用天然或合成化合物）、联合治疗和纳米材料。在这里，全面综述了致病性细菌物种或细菌和真菌之间的不同类型的多微生物相互作用及其相关性。详细探讨了单一化合物、联合治疗和纳米材料对多微生物生物膜的作用机制。本综述提供了各种未来的观点，可以推进控制多微生物生物膜的策略及其可能的作用模式。由于大多数对抗多微生物生物膜的研究都是在体外进行的，因此在体内进行测试以确定不同治疗方法对抗多微生物生物膜的临床效果是至关重要的一步。
